An official website of the United States government
Home
Name
Bizengri
Alternate Names
Zenocutuzumab
Zenocutuzumag-zbco
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
None
NSC Number
None
Primary Site
Lung, pancreas
Histology
NSCLC, adenocarcinoma
Remarks
December 4, 2024 FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri) for adults with the following:
• advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy, or
• advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring a NRG1 gene fusion with disease progression on or after prior systemic therapy.
• advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy, or
• advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring a NRG1 gene fusion with disease progression on or after prior systemic therapy.
Coding
This drug should be coded
